BERWYN, PA — Actum Pharma has announced the appointment of two new executives to drive the launch of a specialized service platform aimed at supporting life science companies in developing and delivering transformative therapies. The hires, Donovan Quill as Chief Strategy Officer of Life Sciences and Bob Gilkin, RPh, MBA, as Chief Commercial and Growth Officer, position the company to address emerging challenges in the biopharma sector while supporting organizations as they pursue market adoption and long-term milestones.
The new platform, developed in collaboration with AscellaHealth, an affiliate delivering tailored solutions to the specialty pharmaceutical industry, is designed to assist companies with navigating funding, development, and commercialization of novel therapies. Both Quill and Gilkin will serve dual roles with Actum and AscellaHealth, leveraging their expertise to provide comprehensive backing to biopharma manufacturers tackling rare and complex medical conditions.
“The stakes are higher than ever for life sciences organizations to ensure they are building a viable and sustainable business to ultimately treat critical patient populations,” said Quill. “[Actum’s] operating partner approach…is a strong complement to the strengths of AscellaHealth, filling critical gaps often experienced by manufacturers as they work to build market penetration and product adoption.”
Quill brings extensive experience in advancing the rare disease community, while Gilkin is recognized for his success in commercial operations and market access. Their leadership complements Actum’s existing executive team, including Chief Engagement Officer Keri Schoenbrun and Chief Operating Officer Doug Ackley. Ackley remarked, “We are thrilled to welcome Donovan and Bob to Actum…Their complementary skills and experiences will help us to deliver increased impact for our life sciences clients and partners.”
The platform’s launch arrives at a crucial time for the life sciences field, as the road to approval and commercialization faces high scientific and regulatory hurdles. With failure rates exceeding 90% in clinical drug development and growing complexity in regulatory oversight, Actum’s initiative offers a timely response to these challenges through a flexible support model tailored to the needs of each therapy and organization.
By combining strategic expertise and comprehensive resources, Actum Pharma’s new platform aims to drive innovation, elevate efficiency, and bring impactful therapies to patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.